(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau

OHP)

l controller de compressa de la compressa de l

(43) International Publication Date 26 February 2004 (26.02.2004)

PCT

(10) International Publication Number WO 2004/016578 A3

- (51) International Patent Classification⁷: C07C 217/10, 311/29, 213/00, 303/40, C07D 215/26, 213/65, 265/36, 277/68
- (21) International Application Number:

PCT/EP2003/008264

- (22) International Filing Date: 24 July 2003 (24.07.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0217225.2

25 July 2002 (25.07.2002) GB

- (71) Applicants (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). BIGGADIKE, Keith [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): COE, Diane, Mary [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). HOLMES, Duncan, Stuart [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,

Stevenage, Hertfordshire SG1 2NY (GB). LOOKER, Brian, Edgar [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).

- (74) Agent: FLORENCE, Julia, Anne; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

[Continued on next page]

(54) Title: ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS

(1)

R13

R¹³

2004/016578 A3

(57) Abstract: The present invention concerns compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, wherein: R^1 is hydrogen or $-XSO_2NR^6R^7$; R^2 and R^3 are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo, phenyl and C_{1-6} haloalkyl and Ar is a group selected from and. Processes for preparing said compounds and pharmaceutical formulations containing them are also described. Compounds of formula (I) are useful in the treatment of respiratory diseases





 before the expiration of the time limit for amending the claims and to be republished in the event of receipt of

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

10 June 2004

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To: GLAXOSMITHKLINE Corporate Intell. Property Attn. Florence, Julia A. (CN925.1)

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

980 Great West Road Brentford, Middlesex TW8 9GS UNITED KINGDOM				
	Date of mailing (day/month/year) 21/04/2004			
Applicant's or agent's file reference				
JAF/PG4858	FOR FURTHER ACTION See paragraphs 1 and 4 below			
International application No.	International filing date			
PCT/EP 03/08264	(day/month/year) 24/07/2003			
Applicant				
GLAXO GROUP LIMITED				
The applicant is hereby notified that the International Search	n Report has been established and is transmitted herewith.			
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claim	The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):			
When? The time limit for filing such amendments is norma International Search Report; however, for more de	When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.			

International Bureau of WIPO Where? Directly to the 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41-22) 740.14.35 For more detailed instructions, see the notes on the accompanying sheet. The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith. 3. | With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that: the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made. 4. Further action(s): The applicant is reminded of the following: Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication. Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later). Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the

Name and mailing address of the International Searching Authority

priority date or could not be elected because they are not bound by Chapter II.

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, __ Fax: (+31-70) 340-3016

Authorized officer

Chantal Meyer

Form PCT/ISA/220 (July 1998)



These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers;
 claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.



INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference FOR FURTHER see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.				
International application No. International filing date (day/month/year) (Earliest) Priority Date (day/month/year)				
PCT/EP 03/08264	24/07/2003	25/07/2002		
Applicant GLAXO GROUP LIMITED				
GLAXO GROUP LIMITED				
according to Article 18. A copy is being tra	of a total of sheets.			
X It is also accompanied by	a copy of each prior art document cited in this	report.		
Basis of the report				
a. With regard to the language, the	international search was carried out on the bas less otherwise indicated under this item.	sis of the international application in the		
Authority (Rule 23.1(b)).	ras carried out on the basis of a translation of the			
was carried out on the basis of the	 b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. 			
	ernational application in computer readable form	n.		
	this Authority in written form.			
· · ·	·			
the statement that the sul	furnished subsequently to this Authority in computer readble form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.			
the statement that the info fumished	the statement that the information recorded in computer readable form is identical to the written sequence listing has been			
2. X Certain claims were fou	nd unsearchable (See Box I).	·		
3. X Unity of invention is lac	· · · · · · · · · · · · · · · · · · ·			
4. With regard to the title,				
the text is approved as su	·			
. —	the text has been established by this Authority to read as follows:			
ARYLETHANOLAMINE BETA	2-ADRENORECEPTOR AGONIST COM	IFOUNDS		
5. With regard to the abstract,				
the text has been establis	the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.			
6. The figure of the drawings to be published with the abstract is Figure No.				
as suggested by the appl		None of the figures.		
because the applicant fair		_		
	characterizes the invention.			



A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C217/10 C07C311/29

C07D213/65

C07D265/36

C07C213/00 C07D277/68 C07C303/40

C07D215/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	WO 95/19336 A (IOVIS BIOMEDICAL AND PHARMACEU; BRON JAN (NL); STERK GEERT JAN (NL);) 20 July 1995 (1995-07-20) claims 1,5-8; examples 1,5-7,9,16 page 15, paragraph 1 - page 16, paragraph 2	1,3,5-7, 12-16
X	EP 0 220 054 A (GLAXO GROUP LTD) 29 April 1987 (1987-04-29) claims 1-3,9,10; examples 16,25 page 4, line 62 - page 5, line 6	1-3,5-8, 12-16
X	EP 0 162 576 A (GLAXO GROUP LTD) 27 November 1985 (1985-11-27) cited in the application claims 1,8,9 page 5, paragraph 3 - page 6, paragraph 3	1,2,5,8, 12-16

X Patent family members are listed in annex.
 'T' tater document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '&' document member of the same patent family
Date of mailing of the international search report
2 1 04 2004
Authorized officer Krische, D



Intern	Application No
PCT/EP	03/08264

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Valegory	Canada a destination, management appropriate, or me to a series and a	
A	DE 35 24 990 A (GLAXO GROUP LTD) 23 January 1986 (1986-01-23) cited in the application claims 1,15,16; examples 1-13 page 15, line 1 - line 29 page 22, line 25 - line 35	1,12-16
	GB 2 140 800 A (GLAXO GROUP LTD) 5 December 1984 (1984-12-05) cited in the application claims 1-11; examples 2-4,6-10 page 2, line 62 - page 3, line 15	1,12-16
1	GB 2 230 523 A (GLAXO GROUP LTD) 24 October 1990 (1990-10-24) cited in the application claims 1-6; example 1 page 3, paragraph 2 - paragraph 4 page 6, paragraph 2 - page 8, paragraph 3	1,12-16
A	DE 40 28 398 A (THOMAE GMBH DR K) 12 March 1992 (1992-03-12) claims 1,7,13	16
	. •	

6





Box I Observation	ons where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Sea	rch Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because the	y relate to subject matter not required to be searched by this Authority, namely:
Althoug body, t compoun	h claim 12 is directed to a method of treatment of the human/animal he search has been carried out and based on the alleged effects of the ds.
an extent tha	y relate to parts of the International Application that do not comply with the prescribed requirements to such at no meaningful International Search can be carried out, specifically: THER INFORMATION sheet PCT/ISA/210
3. Claims Nos. because the	y are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observation	ons where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Sea	rching Authority found multiple inventions in this international application, as follows:
see add	itional sheet
	sult of the prior review under R. 40.2(e) PCT, ditional fees are to be refunded.
1. X As all require searchable of	ed additional search fees were timely paid by the applicant, this International Search Report covers all claims.
2. As all search of any additi	nable claims could be searched without effort justifying an additional fee, this Authority did not invite payment onal fee.
3. As only som covers only	e of the required additional search fees were timely paid by the applicant, this International Search Report those claims for which fees were paid, specifically claims Nos.:
No required restricted to	additional search fees were timely paid by the applicant. Consequently, this International Search Report is the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.

Continuation of Box I.2

Claims Nos.:

Present claims 1-16 relate to compounds of formula (I), salts, solvates or "physiologically functional derivatives" thereof. These "derivatives" are defined by reference to a desirable property, namely that they are "physiologically functional".

The claims cover all compounds having this property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds of formula (I), salts, solvates and as "physiologically functional derivatives" esters thereof.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1,3-7,12-15 in part, 2,8-11

Compounds of formula (I) comprising groups Ar a) or b) useful as beta2-adrenoreceptor agonists and methods and formulations using these compounds.

2. claims: 1,3-7,12-15 in part

Compounds of formula (I) comprising group Ar c) useful as beta2-adrenoreceptor agonists and methods and formulations using these compounds.

3. claims: 1,3-7,12-15 in part

Compounds of formula (I) comprising group Ar d) useful as beta2-adrenoreceptor agonists and methods and formulations using these compounds.

4. claim: 16

Alternative processes for the preparation of compounds of formula (I).

INT NATIONAL SEARCH REPORT

Interi	Application No
PCT/EP	03/08264

	ent document in search report		Publication date		Patent family member(s)	Publication date
WO	9519336	Α	20-07-1995	AU WO	1533495 A 9519336 A1	01-08-1995 20-07-1995
 EP	 0220054	Α	29-04-1987	CN	1048040 A	26-12-1990
				EP	0220054 A2	29-04-1987
				JP US	62174041 A 4908386 A	30-07-1987 13-03-1990
					4900300 A	
EP	0162576	Α	27-11-1985	AT	44955 T	15-08-1989
				AU	581887 B2	09-03-1989
				AU	4134685 A	24-10-1985
				DE	3571808 D1	31-08-1989 18-10-1985
				DK EP	173685 A 0162576 A1	27-11-1985
				JP	60248650 A	09-12-1985
				ÜS	4853381 A	01-08-1989
				ZA	8502853 A	29-01-1986
				GB	2160863 A	02-01-1986
				IL	75485 A	31-10-1988
				NZ	212367 A	26-04-1989
				PH	24383 A	13-06-1990
OE	3524990	Α	23-01-1986	AU	582369 B2	23-03-1989
UE	3324330	^	25 01 1900	AU	4486085 A	16-01-1986
				BE	902876 A1	13-01-1986
				CH	665632 A5	31-05-1988
•				DE	3524990 A1	23-01-1986
				DK	319885 A	14-01-1986
				ES	8609216 A1	16-12-1986
				ES	8707925 A1	16-11-1987 14-01-1986
				FI FR	852755 A 2567510 A1	17-01-1986
				GB	2162842 A ,B	12-02-1986
				GR	851733 A1	26-11-1985
				HU	43556 A2	30-11-1987
				IL	75794 A	31-01-1989
				ΙT	1182061 B	30-09-1987
				JP	61050950 A	13-03-1986
				LU	86002 A1	04-08-1986
				NL NO	8502012 A 852809 A	03-02-1986 14-01-1986
				NO NZ	852809 A 212726 A	24-02-1989
				PH	212726 A 22666 A	14-11-1988
				PT	80806 A ,B	01-08-1985
				SE	8503466 A	14-01-1986
				ZA	8505297 A	30-04-1986
				ZA	8600193 A	29-04-1987
				AT	39350 T	15-01-1989
				CN	86102681 A ,B	28-10-1987 26-01-1989
				DE DK	3566885 D1 13186 A	26-01-1989 11-07-1987
				EP	0178919 A2	23-04-1986
				FI	860107 A ,B,	11-07-1987
				JP	1785301 C	31-08-1993
				JP	4074345 B	26-11-1992
				JP	61148150 A	05-07-1986
				PT	81819 A ,B	01-02-1986
				US	4853382 A	01-08-1989
					400000 M	01 00 1909



Inter Application No
PCT/EP 03/08264

		<u> </u>	101/21	03/ 08204
Patent document cited in search report	Publication date		Patent family member(s)	Publication date
DE 3524990	Α	US	4730008 A	08-03-1988
GB 2140800	A 05-12-1984	AT	390611 B	11-06-1990
		AT	129184 A	15-11-1989
		AU	573212 B2	02-06-1988
		AU	2706484 A	25-10-1984
		BE	899448 A1	18-10-1984
		BE	900835 A4	17-04-1985
		BG	61490 B2	30-09-1997
		CA	1335999 C	20-06-1995
		CA	1336004 C	20-06-1995
		CH	661497 A5	31-07-1987 15-09-1988
		CH CZ	667084 A5 9104028 A3	12-05-1993
		CY	1482 A	08-12-1989
		CZ	285602 B6	15-09-1999
			3414752 A1	18-10-1984
		DE DE	3414752 AT 3448338 C2	19-05-1993
		DE	3448452 C2	05-01-1994
		DK	158092 A	30-12-1992
		DK	201784 A	19-10-1984
		ES	8505641 A1	01-10-1985
		ES	8609209 A1	16-12-1986
1		FΙ	841548 A ,B,	19-10-1984
		FR	2545482 A1	09-11-1984
		GB	2176476 A ,B	31-12-1986
		GR	79925 A1	31-10-1984
		HK	36889 A	12-05-1989
		HU	200160 B	28-04-1990
		ΙE	57237 B1	17-06-1992
		ΙL	71569 A	30-10-1987
1		ΙT	1199112 B	30-12-1988
1		JP	1862136 C	08-08-1994
		JP	5069817 B	01-10-1993
		JP	63264443 A	01-11-1988
		JP	1643826 C	28-02-1992
		JP	3000858 B	09-01-1991
		JP	59199659 A	12-11-1984
		JP	2001385 C	20-12-1995
		JP	6087800 A 7029997 B	29-03-1994 05-04-1995
*		JP KE	7029997 B 3864 A	19-05-1989
		KR	9204186 B1	30-05-1992
		LÜ	85329 A1	04-06-1985
		LU	88265 A9	03-02-1994
}		MX	9203226 A1	01-07-1992
		NL	8401258 A ,B,	16-11-1984
		NO	841568 A ,B,	19-10-1984
		NZ	207885 A	29-11-1988
		NZ	221999 A	29-11-1988
		PH	21574 A	11-12-1987
		PT 	78443 A ,B 	01-05-1984
GB 2230523	A 24-10-1990	NONE		
DE 4028398	A 12-03-1992	DE	4028398 A1	12-03-1992
	== •• •	AT	146774 T	15-01-1997
		AU	8426191 A	30-03-1992
Form DCL/(FA/2) 0 (national farmity reprose) / Individual				

INTERNATIONAL SEARCH REPORT

Inten	Application No
PCT/EP	03/08264

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
DE 4028398		CA	2073042 A1	08-03-1992
		DE	59108433 D1	06-02-1997
		DK	500853 T3	07-04-1997
		WO	9204316 A1	19-03-1992
		EP	0500853 A1	02-09-1992
		ES	2097815 T3	16-04-1997
		GR	3022735 T3	30-06-1997
		ΙE	913136 A1	11-03-1992
		JР	5502455 T	28-04-1993
		JP	3164819 B2	14-05-2001
		NZ	239700 A	27-04-1995
		PT	98884 A ,B	31-07-1992
		US	5393774 A	28-02-1995
		ZA	9107086 A	08-03-1993